论文部分内容阅读
辛塞拉勃公司坦言,该公司1998年的业绩得益于安眠药唑吡坦(zolpidem,Stilnox)的杰出贡献,该品1998年增长率高达21％,达22.42亿法郎(合3.99亿美元)。并披露,它已暂停化疗镇吐剂R-zacopride的开发,因该品Ⅱ期研究进展不顺利。法国集团认为,该品与葛兰素威尔康公司的盐酸昂丹司琼(ondansetron,Zofran)相比,并未表现出较强的功效。R-zacopride的研究结果未曾公布,预定于 2002年在欧
The company said that the company’s performance in 1998 benefited from the outstanding contribution of the hypnosis drug zolpidem (Stilnox). The product’s growth rate in 1998 was as high as 21% to 2.242 billion francs ($3.99 billion). And disclosed that it has suspended the development of chemotherapy antiemetic R-zacopride, because the phase II study of the product is not going well. The French group believes that the product does not show strong efficacy compared with Ondansetron (Zofran) of Glaxo Wellcome. The results of R-zacopride’s study have not been announced and it is scheduled to be in Europe in 2002.